Protocol Ledger

NCT05262270 · Phase II · COMPLETED

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

Interventional Phase II clinical trial protocol NCT05262270 sponsored by University of Texas Southwestern Medical Center in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-18 Enrollment: 427 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05262270
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)427 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05262270
Protocol FieldVerified Registry Value
NCT IdentifierNCT05262270
Consolidated Lead SponsorUniversity of Texas Southwestern Medical Center
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment427 participants (ACTUAL)
Registered Start Date2023-04-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI